Condensed Consolidated Statements of Cash Flows (USD $) In Thousands	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Cash Flows from Operating Activities:
Net Income	$ 12,376	$ 41,495
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	734	757
Loss on extinguishment of debt	0	6,006
(Gain) from change in fair value of hybrid financial instruments	(4,203)	(12,611)
(Gain) from change in fair value of derivative liability - warrants	(2,263)	(9,751)
(Gain) from change in fair value of derivative liability - Series C and D preferred stock and debentures	(12,457)	(31,263)
Interest expense related to convertible debt	2,812	1,551
Interest paid on convertible debt	(1,000)	0
Stock-based compensation expense	58	138
Increase in value of life insurance policies	133	(39)
Changes in operating assets and liabilities
Trade and other accounts receivable	(8)	(271)
Inventories	(35)	12
Prepaid expenses and other assets	(84)	40
Accounts payable and accrued liabilities	17	(351)
Deferred revenue and other current liabilities	409	(367)
Net cash used in operating activities	(3,511)	(4,654)
Cash Flows from Investing Activities:
Acquisition of property and equipment	(6)	(13)
Net cash used in investing activities	(6)	(13)
Cash Flows from Financing Activities:
Proceeds from issuance of Series D preferred stock	0	2,500
Costs attributed to issuance of Series D convertible preferred stock	0	(100)
Borrowing (repayment) of note payable - YA Global	0	(500)
Borrowings under convertible debt instruments, net	3,685	2,865
Net cash provided by financing activities	3,685	4,765
Effect of exchange rate changes on cash	2	(6)
Net increase in cash and cash equivalents	170	92
Cash and cash equivalents, beginning of period	80	198
Cash and cash equivalents, end of period	250	290
Supplemental cash flow information:
Interest paid during the period	1	1
Series C preferred stock converted to common stock	9,320	273
Series D preferred stock converted to common stock	279	0
Convertible Debentures converted to common stock	3,212	0
Deemed dividend on Series D preferred stock issued	0	2,500
Shares issued for acquisition of patent rights	$ 350	$ 0